Prostate Cancer - Results from #460

Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer. August 6, 2024

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies. August 6, 2024

Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. August 6, 2024

De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium. August 5, 2024

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. August 5, 2024

Salvage treatments after focal therapy for prostate cancer - a comprehensive review. August 5, 2024

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review. August 5, 2024

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). August 5, 2024

Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. August 5, 2024

Incidence and Pitfalls of Adipose Tissue Encountered in Prostatic Transurethral Resections and Related Specimens. August 5, 2024

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. August 5, 2024

LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer. August 5, 2024

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. August 5, 2024

Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. August 2, 2024

The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area. August 2, 2024

Artificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy. August 2, 2024

Antiandrogen Withdrawal Syndrome After Discontinuation of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer: A Report of Two Clinical Cases and a Literature Review. August 2, 2024

Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer. August 2, 2024

Race-Based Screening under the Public Health Ethics Microscope - The Case of Prostate Cancer. August 1, 2024

European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. August 1, 2024

Page 24 of 1436